PIRS - Bathi resik saben saham (EPS TTM) Pieris Pharmaceuticals Inc

The development of the Anticalin platform to combat cancer and respiratory pathologies is driving the company, as demonstrated by the annual net income per share trend on the GURU.Markets terminal chart, where -5.47 captures the value of this parameter. The scientific authority of Pieris Pharmaceuticals (PIRS) is based on the creation of unique protein therapies, however, sharp workforce reductions and stagnant testing have limited the business's scalability.

Pieris Pharmaceuticals focuses on high-cost R&D in oncology and respiratory pathologies. The EPS TTM metric measures the final net income allocated per common share over a year. Negative values here reflect investments in science, while their reduction signals an approach toward monetization. Analyzing the trend allows for an assessment of capital management efficiency. The 12-month earnings per share history clearly demonstrates the pace of the business's financial transformation.